secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2022-03-15T23:59:59+00:00
Accession:  0001558370-22-003610
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune reports Q4 2021 net loss of $23.9M ($0.57/share); cash $190.3M; pemvidutide trials on track
--------------------------------------------------------------------------------

- Net loss $23.9M ($0.57 per share) vs $10.6M ($0.29) in Q4 2020; R&D expense doubled to $20.2M on pemvidutide development.
- Cash, equivalents and short-term investments of $190.3M at Dec 31, 2021; revenue $3.3M vs $2.3M.
- Pemvidutide Phase 1b NAFLD trial >90% enrolled; topline data expected Q3 2022.
- Phase 2 MOMENTUM obesity trial (48 wks) initiation expected Q1 2022; interim data at 24 wks in Q4 2022.
- HepTcell Phase 2 chronic hepatitis B trial enrollment ongoing; readout expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000155837022003610/0001558370-22-003610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000155837022003610/alt-20220315x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-003610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer